Hansoh Pharmaceutical Group Files HK$7.9 Billion IPO
July 5, 2019
July 5, 2019
Cleary Gottlieb represented Hansoh Pharmaceutical Group Company Ltd. (Hansoh Pharmaceutical Group) in its HK$7.9 billion initial public offering and listing.
Morgan Stanley and Citi acted as joint sponsors; Morgan Stanley, Citi, UBS, Goldman Sachs, and China Merchants Securities acted as joint global coordinators, joint bookrunners, and joint lead managers; China International Capital Corp. acted as joint bookrunner and joint lead manager; and CMB International acted as joint lead manager for the initial public offering. The offering priced on June 5, 2019, and closed on June 14, 2019. The shares began trading on the Stock Exchange of Hong Kong on June 14, 2019, and the overallotment option was exercised in full on July 5, 2019.
Hansoh Pharmaceutical Group is a China-based pharmaceutical company that is principally involved in the research and development, production, and sale of pharmaceutical products.